Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00381550 · FLOW

Participant flow

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia · Source last updated 2015-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Triapine and Fludarabine Phosphate
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Once patient consented to treatment, treatment began shortly there after.
recruitment Details
Patient's presenting for treatment of a myeloproliferative disease were considered for participation.
Complete source fields
groups
  1. description
    Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Triapine and Fludarabine Phosphate
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Once patient consented to treatment, treatment began shortly there after.
recruitment Details
Patient's presenting for treatment of a myeloproliferative disease were considered for participation.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice